A Clinician S Guide To Nuclear Oncology

In the new edition of this very successful book, European and North American experts present the state of the art in diagnostic and therapeutic radionuclide procedures. The aim is to examine established and emerging clinical applications in detail, rather than to consider everything included in the comprehensive texts already available within the field. This “practical” approach ensures that the book will be a valuable guide for nuclear medicine physicians, technologists, students, and interested clinicians alike. This edition of Clinical Nuclear Medicine has been extensively revised to take account of recent developments. The roles of SPECT/CT, PET/CT, and PET/MRI are clearly explained and illustrated, and the coverage extended to encompass, for example, novel PET tracers and therapeutic radionuclides, advanced techniques of brain imaging, and the development of theranostics. Readers will be fully persuaded of the ever-increasing value of nuclear medicine techniques in depicting physiology and function and complementing anatomic modalities such as CT, MRI, and ultrasound.

This guide provides practical information that will assist clinicians involved in the diagnosis, assessment, treatment, and follow-up care of patients with triple-negative breast cancer. After opening chapters on the pathologic evaluation, clinical presentation, genetics, and imaging features, the full range of current treatment approaches is thoroughly reviewed from a multidisciplinary perspective. Readers will find up-to-date information and guidance on surgical management, radiation therapy, tailored adjuvant therapy, neoadjuvant treatment, systemic treatment for metastatic disease, molecular profiling, and targeted therapy. The coverage is completed by discussion of special issues in young women with triple-negative breast cancer and individualization of the management approach in older patients affected with the disease. All healthcare professionals who care for patients with triple-negative breast cancer will find the book to be an invaluable source of expert advice on the issues faced in real-world practice.

This pocket book offers a rapid and concise overview of the utility of PET/CT in the management of patients with cancer of unknown primary (CUP). Readers will gain an appreciation of the unique information provided by PET/CT on the molecular and metabolic changes associated with CUP, which can occur in the absence of corresponding anatomical alterations. Characteristic imaging appearances are documented with the aid of a series of teaching cases that serve to illustrate the potential improvements in patient management that may be achieved through early use of PET/CT in the diagnostic pathway. In addition, the relation of the clinical and pathological background to imaging is explained. The book is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging (compiled under the auspices of the British Nuclear Medicine Society) and will be an excellent asset for all clinicians, nuclear medicine physicians, radiologists, radiographers, and nurses who routinely work in multidisciplinary teams involved in the management of these patients.

This work has true international scope, being a unique European/American joint venture that focuses on the state of the art in both diagnostic and therapeutic radionuclide methodology. Pertinent clinical applications are emphasized rather than attempting to cover everything included in the several large comprehensive texts available in our field. This "practical" approach should make it an essential guide to nuclear medicine physicians, technologists, students and interested clinicians alike.

Thoroughly revised and extensively expanded, this encyclopedic, highly acclaimed title addresses all aspects of the etiology, pathogenesis, diagnosis, initial treatment and long-term management of all varieties of thyroid cancer. Expertly edited by Drs. Leonard Wartofsky and Douglas Van Nostrand, this gold standard reference is divided into 11 Parts: General Considerations on Thyroid Cancer; General Considerations on Nuclear Medicine; the Thyroid Nodule; Well-Differentiated Thyroid Cancer; Variants of Thyroid Cancer, Undifferentiated Tumors: Medullary Thyroid Carcinoma; Undifferentiated Tumors: Thyroid Lymphoma; Undifferentiated Tumors: Anaplastic Thyroid Cancer; New Frontiers and Future Directions; and Additional Resources. With exceptional breadth and depth, the book includes chapters dedicated to isotopes, isotope uptake and scanning procedures such as SPECT/CT, radioiodine ablation (with or without recombinant human TSH), stunning, dosimetry (with or without recombinant human TSH), Octreotide and FDG-PET scanning and other alternative imaging modalities. There is a valuable reference atlas of scan images and illustrations, and a scholarly summary of the side effects of radioiodine and how to avoid or minimize adverse effects of treatment. In addition to an updated section on ultrasonography of the thyroid gland, new sections have been added, including ones on ultrasonography of cervical lymph nodes and imaging for thyroid cancer employing computerized tomography (CT), positron emission tomography (PET) and magnetic resonance imaging (MRI). An indispensable reference source with chapters written by the field’s leading authoritative experts, Thyroid Cancer: A Comprehensive Guide to Clinical Management, Third Edition, will be of great interest to not only pathologists, endocrine surgeons, endocrinologists, nuclear medicine physicians, and oncologists but all clinicians with an interest in thyroid cancer.

This book offers a practical and modern update on radioisotope therapy. Clinically oriented, it provides a thorough guide to patient management, with the latest indications and procedures for the current radioisotopic treatments. It addresses the clinical problems associated with each respective pathology, discussing the management of patients (diagnosis and non-radioisotope therapy), the radiopharmaceuticals available today, and the current radioisotopic procedures. Wherever possible, information on dosimetry is included at the end of each topic, together with a list of and comments on the most recent guidelines with their recommendations for radiometabolic therapy. The book is divided into six main sections: thyroid diseases, hepatic tumors (HCC and hepatic metastases), bone metastases from prostate cancer, lymphomas, and neuroendocrine tumors. The last section is dedicated to new perspectives of radioisotope treatment. Based on contributions from of a multidisciplinary team of specialists: oncologists, surgeons, endocrinologists, hematologists, urologists, radiopharmacists and nuclear medicine physicians, it provides a comprehensive analysis of the position of radioisotope treatments among the various therapeutic options. Readers interested in targeted therapy, radiometabolic therapy, radioimmunotherapy and radiometabolic imaging will find this book both informative and insightful.